Medanta to operate and manage 750 bed super speciality hospital in Pitampura, New Delhi
Medanta is expected to incur a project capex of ~Rs. 600 crores in next 3-4 years
Medanta is expected to incur a project capex of ~Rs. 600 crores in next 3-4 years
The company uses iPS cells to develop treatments for diseases relating to the kidney
ISB 2001 demonstrated a favorable safety and tolerability profile, and an overall response rate (ORR) of 75% in r/r MM
The recognition from Malaysia's NPRA, a member of PIC/S, opens doors to new global business opportunities
Partnership to Combine AbbVie's Oncology Expertise with EvolveImmune's Proprietary EVOLVE T-Cell Engager Platform to Develop Novel Multispecific Therapeutic Antibodies for Cancer
Revenue at Rs 3,623 crore, EBITDA at Rs 718 crore
The US District Court of New Jersey decided to grant a preliminary injunction delaying the launch of LEQSELVI
The inspection concluded with the issuance of Form 483 with four observations which are procedural in nature
CMG1A46 is an investigational T cell-engager with potential to deeply deplete uncontrolled B cells present in autoimmune diseases such as lupus
The INTerpath-009 clinical trial demonstrates continued expansion of the INTerpath clinical program
Subscribe To Our Newsletter & Stay Updated